Warner-Lambert retains Zantac 75 North America rights after Glaxo venture dissolves.
This article was originally published in The Tan Sheet
Executive Summary
WARNER-LAMBERT ZANTAC 75 RIGHTS IN NORTH AMERICA RETAINED following dissolution of the firm's joint venture with Glaxo Wellcome for over- the-counter drugs. Under the new arrangement, announced Aug. 3, Warner-Lambert will pay Glaxo Wellcome for the cost of supplying the H2 antagonist ranitidine; there is no royalty component to the agreement. Zantac 75 sales in the U.S. through the half totaled $84 mil. Worldwide sales in 1997 were $161 mil. Zantac 75 is third in the acid blocker market in terms of dollar sales and had a 10.5% market share in 1997 in food, drug and mass merchandise retail channels, according to Information Resources, Inc. (Chicago).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning